33620 Results

People

  1. Ladanyi
    Ladanyi
  2. Giralt
    Giralt
  3. Motzer
    Motzer
  4. Reuter
    Reuter
  5. Perales
    Perales
  6. Scher
    Scher
  7. Zelenetz
    Zelenetz
  8. Berger
    Berger
  9. Al-Ahmadie
    Al-Ahmadie
  10. O'Reilly
    O'Reilly

Groups

  1. Department of Medicine (15822)
  2. Solid Tumor Oncology Division (9435)
  3. GSK Faculty (7076)
  4. Hematologic Malignancies, Division of (6210)
  5. Center for Hematologic Malignancies (6017)
  6. Survivorship Research (5192)
  7. Department of Pathology and Laboratory Medicine (5172)
  8. Surgery (4871)
  9. Sloan Kettering Institute Faculty (3826)
  10. Sloan Kettering Institute Postdocs (3612)
  1. "Meeting abstract"
Formats
  1. Meeting Abstract (33620)
Groups
  1. Department of Medicine (15822)
  2. Solid Tumor Oncology Division (9435)
  3. GSK Faculty (7076)
  4. Hematologic Malignancies, Division of (6210)
  5. Center for Hematologic Malignancies (6017)
  6. Survivorship Research (5192)

More Groups

People
  1. Marc Ladanyi (641)
  2. Sergio Giralt (632)
  3. Robert Motzer (574)
  4. Victor Reuter (568)
  5. Miguel-Angel Perales (482)
  6. Howard Scher (463)

More People

Years
  1. 2025 (295)
  2. 2024 (1694)
  3. 2023 (1954)
  4. 2022 (2196)
  5. 2021 (1731)
  6. 2020 (1901)

More Years

Publications
  1. Journal of Clinical Oncology (6252)
  2. Blood (3939)
  3. Laboratory Investigation (1846)
  4. Cancer Research (1822)
  5. International Journal of Radiation Oncology, Biology, Physics (1643)
  6. Modern Pathology (1494)

More Publications

Publishers
  1. American Society of Clinical Oncology (6251)
  2. Elsevier Inc. (4694)
  3. American Society of Hematology (3939)
  4. American Association for Cancer Research (3045)
  5. Nature Publishing Group (2151)
  6. Oxford University Press (2096)

More Publishers

Results (33620)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Brentuximab vedotin plus chemotherapy for stage III/IV classical Hodgkin lymphoma: 4-year update of the ECHELON-1 study
    Meeting Abstract

    Radford, J.; Bartlett, N.; Straus, D.; Dlugosz-Danecka, M.; Alekseev, S.; Illes, A.; Lech-Maranda, E.; Feldman, T.; Smolewski, P.; Savage, K.; more...
    British Journal of Haematology (2020)

    Fulltext@MSK | Save
  • Cost-effectiveness of a 24-month fixed duration of venetoclax in combination with rituximab in relapse/refractory chronic lymphocytic leukaemia
    Meeting Abstract

    Coll Bastus, N.; Bennison, C.; Durno, N.; Sail, K.; Alexiou, D.; Mato, A.; Eyre, T. A.; Follows, G.
    British Journal of Haematology (2020)

    Fulltext@MSK | Save
  • Response to brentuximab vedotin plus CHP according to CD30 expression in the ECHELON-2 trial
    Meeting Abstract

    Illidge, T.; Horwitz, S.; Iyer, S.; Bartlett, N.; Kim, W. S.; Belada, D.; Feldman, T.; Illes, A.; Jacobsen, E.; Huttmann, A.; more...
    British Journal of Haematology (2020)

    Fulltext@MSK | Save
  • Correlation of Epstein-Barr virus-specific cytotoxic T lymphocyte precursors (EBV-CTLp) after tabelecleucel with response and survival in rituximab relapsing or refractory EBV plus post-transplant lymphoproliferative disease (PTLD)
    Meeting Abstract

    Aftab, B. T.; Shen, R. R.; Guzman-Becerra, N.; Sun, Y.; Forozan, F.; Prockop, S.; Doubrovina, E.; O'Reilly, R. J.; Li, X.; Hiremath, M.; more...
    Journal of Clinical Oncology (2020)

    Fulltext@MSK | Save
  • Ixazomib-dexamethasone versus physician's choice in patients with relapsed/refractory systemic AL amyloidosis: Primary data from the phase 3 TOURMALINE-AL1 trial
    Meeting Abstract

    Wechalekar, A. D.; Dispenzieri, A.; Kastritis, E.; Schonland, S. O.; Kim, K.; Sanchorawala, V.; Landau, H. J.; Kwok, F.; Suzuki, K.; Comenzo, R. L.; more...
    British Journal of Haematology (2020)

    Fulltext@MSK | Save
  • Updated results of a phase Ib/II randomised study: Polatuzumab vedotin (Pola) plus bendamustine (B) and rituximab (R) in relapsed/refractory diffuse large B-cell lymphoma (R/R DLBCL)
    Meeting Abstract

    Sehn, L. H.; McMillan, A.; Matasar, M. J.; Flowers, C. R.; Kamdar, M.; Hertzberg, M.; Assouline, S.; Kim, T. M.; Kim, W. S.; Ozcan, M.; more...
    British Journal of Haematology (2020)

    Fulltext@MSK | Save
  • Safety and efficacy results from TRANSCEND NHL 001, a multicenter phase 1 study of lisocabtagene maraleucel (liso-cel) in relapsed/refractory large B-cell lymphoma
    Meeting Abstract

    Abramson, J.; Palomba, M. L.; Gordon, L.; Lunning, M.; Wang, M.; Arnason, J.; Mehta, A.; Purev, E.; Maloney, D.; Andreadis, C.; more...
    British Journal of Haematology (2020)

    Fulltext@MSK | Save
  • Whole genome profiling of adult B-other acute lymphoblastic leukaemia on the UKALL14 trial
    Meeting Abstract

    Leongamornlert, D.; Barretta, E.; Lee, S.; Creasey, T.; Mitchell, R.; Kirkwood, A.; Clifton-Hadley, L.; Patrick, P.; Campbell, P.; Patel, B.; more...
    British Journal of Haematology (2020)

    Fulltext@MSK | Save
  • Genetic and genomic characterisation of older adults with acute lymphoblastic leukemia treated on the UKALL14 and UKALL60 + clinical trials
    Meeting Abstract

    Creasey, T.; Barretta, E.; Kirkwood, A.; Schwab, C.; Patrick, P.; Clifton-Hadley, L.; Patel, B.; Menne, T.; McMillan, A.; Morley, N.; more...
    British Journal of Haematology (2020)

    Fulltext@MSK | Save
  • Gilteritinib prolongs survival in patients with FLT3-mutated relapsed/refractory acute myeloid leukaemia who have common AML comutations or a high FLT3-internal tandem duplication allelic ratio
    Meeting Abstract

    Levis, M. J.; Perl, A. E.; Martinelli, G.; Cortes, J. E.; Neubauer, A.; Berman, E.; Montesinos, P.; Baer, M. R.; Larson, R. A.; Chou, W. C.; more...
    British Journal of Haematology (2020)

    Fulltext@MSK | Save